Chapter 18

Randomised Controlled Trials in the Primary Treatment of Hepatocellular Carcinoma

Monica Robotin

Abstract

While thousands of randomized controlled trials (RCT) inform the treatment of many of the most lethal cancers, in hepatocellular carcinoma (HCC), only 77 RCT studies were published between 1978 and 2005. This systematic review sought to identify RCTs pertaining to the treatment of liver cancer published from January 2006 to July 2009 and evaluate their methodological quality. Thirty RCTs published in English were identified. Most (18) originated in Asia, one third in Europe and two were multi-country studies. A total of 4,139 patients were enrolled in these RCTs, for a mean of 138 patients per trial. 73% of these trials were of high methodological quality. The RCTs found that using monoclonal antibodies or gene therapy in conjunction with liver transplantation may extend transplant indications and that the use of interferon, lipiodol or adoptive immunotherapy in conjunction with liver resection may improve survival, but that this would need validation by larger studies. Radiofrequency ablation (RFA) is equally effective, and has fewer complications than liver resection. RFA is superior to percutaneous ethanol injection (PEI) for local disease control and combining RFA and PEI improves overall survival. The role of arterial occlusion during RFA awaits further validation. Transarterial chemoembolization (TACE) combined with RFA and immuno-modulators may warrant future exploration. Two large, high quality sorafenib trials confirmed the role of this agent in the systemic treatment of HCC. The octreotide trials have overall been disappointing, but benefits may exist for HCCs expressing somatostatin receptors. Although the last 4 years have witnessed significant progress in this field, the average of 9 RCTs per year for HCC treatment remains well behind the level of research activity in other cancers.

Total Pages: 174-195 (22)

Purchase Chapter  Book Details